1. Introduction {#sec1}
===============

Posttraumatic stress disorder (PTSD) has been conceptualized as a failure to recover from normative acute trauma-related symptoms ([@bib41]). As such, there has been growing attention to laboratory studies measuring extinction of conditioned fear and retention of extinction learning. Several studies have shown that PTSD and normal comparison groups often, but not always, show comparable acquisition and extinction of conditioned fear, while individuals with PTSD demonstrate impaired extinction retention ([@bib20], [@bib21]).

Given significant sex differences in the development and maintenance of PTSD ([@bib5]), it is possible that specific biological factors place women at greater risk for developing this disorder ([@bib30]). For example, hormone signaling in the central nervous system (CNS) has been shown to influence the retention of extinction learning ([@bib16]), and the associations appear to differ for women with and without PTSD ([@bib29]). Healthy women with relatively high levels of estradiol and/or progesterone during extinction learning better retain the learning when subsequently tested ([@bib29]; [@bib22]). In contrast, women with PTSD show *poorer* retention of extinction learning during the mid-luteal phase (mLP) of the menstrual cycle when both estradiol and progesterone levels are high, compared to the early follicular phase (eFP) when both estradiol and progesterone are low and stable ([@bib29]). As these effects could not be attributed to PTSD-related deficits in either estradiol or progesterone, we considered whether the PTSD-related deficits in extinction learning during the mLP might be due to reduced conversion of progesterone into the stereoisomers allopregnanolone (Allo) and pregnanolone (PA), neurosteroids that equipotently and positively modulate the effects of gamma-amino-butyric-acid (GABA) at GABA~A~ receptors ([@bib37]; [@bib31]).

Indeed, a marked decrease in the level of Allo + PA (measured together by gas chromatography-mass spectrometry: GC-MS) was observed in the cerebrospinal fluid (CSF) of women with PTSD in association with increased PTSD reexperiencing and depressive symptoms ([@bib37]). A PTSD-related decrease in the ratio of Allo + PA to 5α-dihydroprogesterone (5α-DHP, the immediate steroid precursor for Allo) also was found ([@bib37]) and was replicated in plasma ([@bib31]), suggesting the presence of a PTSD-related deficiency in the expression or activity of the enzyme 3α-hydroxysteroid dehydrogenase (3α-HSD). In plasma, PTSD-related decreases in this ratio were evident both at rest and after exposure to a stressful fear conditioning procedure ([@bib31]), suggesting that measurement of this ratio in a resting plasma sample might feasibly serve as a quantitative trait marker for 3α-HSD deficiency in both the CNS and periphery of women with PTSD.

In turn, preclinical work has demonstrated the importance of Allo in extinction learning and retention. Allo-deficient male mice, compared to mice with normal Allo levels, are slow to extinguish conditioned contextual fear responses and exhibit greater spontaneous recovery of conditioned fear after completion of extinction learning ([@bib32]; [@bib28]; [@bib17]). Furthermore, a single systemic injection of either a synthetic Allo-derivative (ganaxolone) ([@bib32]) or N-palmitoylethanolamine (PEA: a peroxisome proliferator-activated receptor-alpha agonist that induces Allo synthesis) ([@bib17]) to Allo-deficient mice after one brief exposure to a fear-conditioned context markedly reduced freezing during subsequent extinction training sessions and prevented the spontaneous recovery of contextual fear after completion of extinction learning. These findings suggest that Allo-based compounds might be used to block fear memory reconsolidation, correct deficits in extinction learning, and/or enhance extinction learning retention related to Allo deficiency ([@bib32]; [@bib17]; [@bib36]).

Based on these clinical and preclinical findings, we evaluated the relationship between extinction retention and deficient production of Allo and PA in women with PTSD. We are reporting results from secondary analyses of data collected during our previously published study of fear conditioning across the menstrual cycle in trauma-exposed women with and without PTSD ([@bib29], [@bib31]). Specifically, we assessed whether extinction retention deficits that were most pronounced in the mLP were associated with either lower resting plasma Allo + PA levels or the ratio of (Allo + PA) to 5α-DHP. We also assessed whether extinction retention deficits were related to the Allo + PA to dehydroepiandrosterone (DHEA) ratio. DHEA is an adrenally-derived neuroactive steroid that may compete with Allo and PA effects by allosteric antagonism of GABA~A~ receptors. DHEA also facilitates the function of N-methyl-D-aspartate (NMDA) receptors ([@bib8]). Previous studies in men and follicular phase women demonstrated somewhat stronger correlations between PTSD symptoms and the CSF (Allo + PA)/DHEA ratio than CSF Allo + PA levels alone ([@bib37], [@bib39]).

As described elsewhere ([@bib31]), each study participant was tested during both the eFP and mLP. Based on our previous findings, we hypothesized that an association between Allo + PA levels or the (Allo + PA)/5α-DHP ratio and extinction retention would be strongest for the women with PTSD during the mLP when PTSD-related extinction retention deficits are most pronounced ([@bib29]). We also noted that resting plasma Allo + PA and DHEA levels in our subjects were comparable during the eFP, whereas during the mLP, Allo + PA levels were about 6 times higher than DHEA levels, which do not change across the menstrual cycle (see Results section below: [Table 1](#tbl1){ref-type="table"}). This suggested that DHEA might not be able to compete well with the effects of Allo and PA on GABA~A~ receptor function during the mLP. Therefore, we hypothesized that there would be a stronger relationship between the (Allo + PA)/DHEA ratio and extinction retention during the eFP than mLP.Table 1Neurosteroid means and SDs by menstrual cycle phase (pg/mL).Table 1Early Follicular PhaseMid-luteal PhaseP-valueMeanSDMeanSD**Overall Sample** Allo + PA260.11217.131091.61498.69\<.001 5α-DHP854.65675.65932.58610.55.231 DHEA190.74126.09170.34102.32.865**PTSD Group** Allo + PA179.33139.941360.89391.80.004 5α-DHP1082.59854.791208.42716.49.109 DHEA164.03154.38145.8195.30.820**Trauma Control Group** Allo + PA340.89256.74822.33460.23.055 5α-DHP626.71350.01656.73333.94.945 DHEA217.4691.34194.88108.68.820[^1]

2. Methods and materials {#sec2}
========================

2.1. Participants {#sec2.1}
-----------------

Participants included 18 trauma-exposed women (*M*~*Age*~ = 28.61 years, *SD* = 8.33) with PTSD (n = 9) and without PTSD (trauma-exposed controls, TC; n = 9), who were a subset of participants from a larger investigation examining psychophysiologic responses to provocative stimuli across the menstrual cycle ([@bib29], [@bib31]). Participants in the current study met the inclusion and exclusion criteria for the larger study and: a) had a complete set of blood biomarkers, b) had valid skin conductance (SC) measures available for both phases of the menstrual cycle, and c) were SC responders across the 4 laboratory sessions. The reduced sample size in this secondary analysis, compared to previous papers, reflects the large number of participants who were either SC non-responders or for whom we were unable to start an IV for blood draws at one laboratory session or another in the parent study ([@bib29], [@bib31]). Women in the PTSD group met criteria for a PTSD diagnosis based on DSM-IV criteria, as assessed with the Clinician Administered PTSD Scale (CAPS) ([@bib4]), and had a total CAPS score ≥ 40. Women in the TC group experienced at least one DSM-IV PTSD Criterion A traumatic event, but did not meet criteria for: a) current, partial, or lifetime PTSD, b) any other current Axis I psychological disorder, with the exception of specific phobia or public speaking phobia, or c) more than a single episode of past major depression.

Participants were required to have a normal physical exam and standard screening medical laboratory test results. Exclusion criteria included: infectious illness, organic brain disorder, major neurological problems, endocrine disorders, psychotic disorders, bipolar I disorder, active substance or alcohol abuse or dependence within the past 6 months, irregular menstrual cycle, use of hormonal contraceptives, current pregnancy, and current participation in trauma-focused psychotherapy. Psychotropic medications, as well as other medications that could affect psychophysiological responding or neuroactive steroid levels, were not allowed during the month before the experimental procedures (or longer if an antidepressant with a long half-life).

2.2. Fear conditioning procedures {#sec2.2}
---------------------------------

Participants completed the fear conditioning procedures during both the eFP of the menstrual cycle, 1--5 days from the start of menses, and the mLP, 6--10 days after the luteinizing hormone (LH) surge. The menstrual cycle phase during which participants first completed the conditioning procedures was determined by random assignment.

The following procedures were used to avoid potential confounding influences on neurosteroid hormone levels: a) laboratory sessions were scheduled between 1:00 p.m. and 3:00 p.m., b) participants were asked to abstain from alcohol for 1 week, and other illicit substances for 2 weeks, prior to their visits, c) nicotine users (n = 2) were asked to abstain from nicotine for 1 h prior to arrival at the laboratory, and d) participants were asked to abstain from caffeine and food for 4 h and 2--3 h, respectively, prior to arriving at the laboratory. Abstinence was verified at each study visit by alcohol breathalyzer and urine drug tests. Participants also took a urine pregnancy test at each study visit.

Fear acquisition (conditioning), extinction learning, and extinction retention procedures occurred on 2 consecutive days and followed a standard laboratory paradigm ([@bib29]; [@bib26]). The unconditioned stimulus (UCS) was a 500-ms electric pulse generated by a Coulbourn Finger Stimulator set at a level determined by the participant to be "highly annoying but not painful" during a previous screening session and delivered through electrodes attached to the second and third fingers of the left hand. The conditioned stimuli (CSs) were represented by 2 different colored shapes (e.g., blue vs. white circles). During the acquisition phase, one colored shape was paired with the electric pulse (CS+), while the second colored shape was not (CS-). A different set of colors and shapes was used during the conditioning session that occurred in the alternate menstrual cycle phase. Participants were seated 4 feet from a monitor that displayed the 16-cm colored stimuli.

### 2.2.1. Day 1 {#sec2.2.1}

The electrodes used to measure SC and administer the UCS were attached and participants received instructions for the study procedures. They were told that there were 3 phases during which they would see 2 different colored shapes. Although they were told that they would receive the electrical stimulus during the second phase of the task (i.e., the fear acquisition phase), they were not informed about the possible presence or absence of the electrical stimulus during the third phase (i.e., the extinction learning phase).

Next, the participant underwent a 5-min baseline recording period followed by completion of the 3 task phases: a) habituation, b) acquisition, and c) extinction learning. During the habituation phase, participants were shown 5 presentations each of the to-be CS+ and CS- (i.e., presentation of the 2 different colored shapes without the electrical stimulus). During the acquisition phase, they were shown 5 presentations each of the CS+ and CS- with the 500-ms electrical stimulus occurring immediately after each CS + offset. During the extinction learning phase, they were shown 10 presentations of the CS+ and CS- without administration of the electrical stimulus. Each CS was presented in pseudorandom order for 8 s (inter-trial interval = 20 ± 5 s).

### 2.2.2. Day 2 {#sec2.2.2}

Following attachment of the SC recording electrodes and finger stimulator, participants were told, "Two different colored shapes will be presented on the monitor. There may also be electrical stimulus administration." Following a 5-min baseline recording, participants viewed 10 presentations of the CS+ and CS- with a shock administered following the fifth CS + only. Because the shock was administered in the interval after the fifth CS + trial, only responses to the first 5 CS+ and CS- presentations were used to assess extinction retention.

2.3. Psychophysiology measures {#sec2.3}
------------------------------

A Coulbourn Modular Instrument System (Allentown, PA) was used to administer the conditioning protocol. SC level was measured by an Isolated Skin Conductance coupler using a 0.5 V constant direct current through 8-mm Ag/AgCl surface electrodes filled with isotonic paste and placed on the hypothenar surface of the non-dominant hand ([@bib10]).

### 2.3.1. Response scores {#sec2.3.1}

Prior to calculating SC response (SCR) scores, data were screened for recording artifacts and outliers. Next, participants were screened to ensure that they were SC responders (i.e., the average unconditioned response to the 5 electrical stimulus presentations during acquisition was \>0.1 μS). All participants in this study completed the conditioning task during both menstrual cycle phases and were SC responders across the 4 laboratory sessions included in SCR analyses ([@bib29]).

SCR scores for each CS presentation were calculated by subtracting the mean SC level during the 2-s interval immediately prior to CS onset from the highest SC level recorded during the 8-s CS interval. SCR values were then square root transformed. The percentage of missing SCR scores for all participants with SC data ranged from 0 to 16% (*M* = 4.3%, *SD* = 5.0%) ([@bib29]). Missing scores were replaced using multivariate imputation by chained equations based on random forest recursive partitioning ([@bib45]), and analyses reflect pooled outcomes from 5 imputed datasets.

2.4. Menstrual cycle phase monitoring and verification {#sec2.4}
------------------------------------------------------

For eFP testing, participants notified study staff when they began menses and were scheduled for their visit 1--5 days later. For mLP testing, participants tested for their LH surge using a home ovulation kit. They were scheduled for their mLP visit 6--10 days later. Menstrual cycle phase was confirmed by assay of progesterone and 17β-estradiol levels in plasma collected prior to psychophysiological testing. For the eFP, the mean 17β-estradiol level was 25.7 pg/mL (*SD* = 11.6) and the mean progesterone level was 0.43 ng/mL (*SD* = 0.23). For the mLP, the mean 17β-estradiol level was 73.6 pg/mL (*SD* = 20.8) and the mean progesterone level was 12.3 ng/mL (SD = 6.9). Plasma concentrations of progesterone and 17β-estradiol levels were measured by a solid-phase radioimmunoassay (RIA) (Siemens Healthcare Diagnostics, Deerfield, Ill). The progesterone assay had an intra-assay coefficient of variation (CV) of \~4% and an inter-assay CV of \~6%. The standard range was from 0.1 to 40 ng/mL, with an assay sensitivity of \~0.03 ng/mL. The estradiol assay had a sensitivity of 8 pg/mL and a working range of 12--3900 pg/mL. At the 50% intercept, the intra- and inter-assay CVs for this assay were 4% and 7%, respectively.

2.5. Measurement of neurosteroids {#sec2.5}
---------------------------------

For each menstrual cycle phase, we investigated plasma Allo, PA, and 5α-DHP, as well as salivary DHEA levels at a resting baseline, 45 min after placement of an intravenous line and electrodes, and before the fear conditioning and extinction task on day 1 of the 2-day laboratory paradigm. Resting day 1 eFP and mLP plasma and saliva steroid levels were used to assess associations with day 2 eFP and mLP indices of extinction retention, respectively.

Samples collected by blood draw or collection of saliva into a tube (without cotton insert) were immediately placed on wet ice and centrifuged at 3000 rpm for 20 min. Plasma (500 μL) and saliva (1000 μL) then were aliquotted into cryotubes tubes for storage at −80 °C. As previously described ([@bib37]; [@bib31]; [@bib33]), the plasma samples were extracted in ethylacetate and lyophilized, after which Allo, PA, and 5α-DHP were separated using HPLC and measured by GC-MS. Saliva DHEA concentrations were measured by an enzyme-linked immunoassay (Salimetrics LLC, Carlsbad, CA) with a standard curve range of 10.2 pg/mL - 1000 pg/mL; the linear range was from 20 to 500 pg/mL. The functional sensitivity of the assay was 8.32 pg/mL DHEA. The assay\'s average intra-assay CV was 5.6%, while the average inter-assay CV was 8.2%. The DHEA antibody exhibits only 0.063% cross-reactivity with DHEA-sulfate.

2.6. Data analytic plan {#sec2.6}
-----------------------

The primary aim of this study was to test whether deficits in production of Allo and PA might underlie extinction retention deficits observed in women with PTSD, compared to trauma-exposed women without psychopathology.

To calculate extinction retention ([@bib22]), we averaged the first 5 CS + trials and first 5 CS- trials during day 2 extinction retention testing and subtracted the average CS- SCR from the average CS + SCR. Similarly, CS + minus CS- SCR difference scores were calculated for early extinction learning and late extinction learning on day 1 ([@bib22]). Extinction learning was calculated separately for early and late extinction because we\'d observed increased (although not statistically significant) differential SCR during late vs. early extinction ([@bib22]). We then used these variables to calculate two separate extinction retention scores for the eFP and mLP (i.e., extinction retention subtracting early extinction; extinction retention subtracting late extinction). Larger (i.e., more positive) difference scores indicate *poorer* extinction retention.

We calculated the mean and standard deviation for resting state biomarkers Allo + PA, 5α-DHP, and DHEA, for the eFP and mLP. These measurements violated the normality assumption, as determined by the Shapiro-Wilk test and Q-Q plots. Thus, we used the Wilcoxon signed rank test to determine if there were significant differences between eFP and mLP for each biomarker. These analyses were computed in the overall sample, and within each diagnostic group (PTSD and TC).

We used a linear regression modeling to test the relative predictive effects of diagnostic group status (PTSD vs. TC), resting state biomarkers of interest, i.e., Allo + PA, (Allo + PA)/5α-DHP, and (Allo + PA)/DHEA, and their interaction on extinction retention. Separate models were used to examine these relationships during the eFP and mLP. Spearman\'s rank-order correlations were performed between the two indices of extinction retention and the plasma biomarkers of interest for each phase of the menstrual cycle and for the PTSD and TC groups separately. These correlation coefficients were computed to assist in interpreting significant interactions. Because of the small sample size, these correlation coefficients also were used in an exploratory manner as estimates of effect size in order to inform the design of possible future studies in larger samples. Spearman\'s correlations were used in lieu of Pearson\'s correlations due to the small sample size (n = 9 in each diagnosis group) and the violation of the normality assumption for several of the extinction retention and plasma biomarker measures. For all statistical analyses described above, a *p-*value of \< .05 was considered statistically significant.

3. Results {#sec3}
==========

Descriptive statistics for Allo + PA, 5α-DHP, and DHEA and are presented in [Table 1](#tbl1){ref-type="table"}.

The linear regression model examining the effects of Allo + PA on extinction retention calculated in comparison to early extinction during the mLP revealed a main effect of diagnosis such that individuals with PTSD showed poorer extinction retention (β = 1.147, *p* = .001; [Table 2](#tbl2a){ref-type="table"}a), a finding consistent with that previously reported for the larger sample ([@bib22]). There was also a significant diagnosis by Allo + PA interaction (β = -.0008, *p* = .003) indicating a strong positive relationship between resting plasma Allo + PA levels and better extinction retention for the PTSD, but not TC group ([Table 2](#tbl2a){ref-type="table"}a). Parallel results were found for the mLP model examining extinction retention calculated in comparison to late extinction (diagnosis main effect: β = 1.135, *p* = .005; diagnosis X Allo + PA interaction: β = -.0009, *p* = .008). The correlations between mLP Allo + PA levels and extinction retention based on early and late extinction are depicted for the PTSD and TC groups in [Table 3](#tbl3){ref-type="table"} and [Fig. 1](#fig1){ref-type="fig"}a and b.Table 2aExtinction retention deficits as predicted by diagnostic group, Allo + PA, and the interaction between diagnostic group and Allo + PA.Table 2aFixed EffectCoefficientSET-ratioUnadjusted p-valueeFPEarly Extinction Interceptγ00.335.1851.805.093 Dx (0,1)γ01-.312.259−1.203.249 Allo + PAγ02-.000369.000443-.832.419 (Allo + PA) x Dxγ03.000637.000927.688.503***Late Extinction*** Interceptγ00.295.2161.371.192 Dx (0,1)γ01-.133.302-.441.666 Allo + PAγ02-.000420.000516-.815.429 (Allo + PA) x Dxγ03-.000083.001077-.077.940**mLP*Early Extinction*** Interceptγ00-.056.127-.442.665 Dx (0,1)γ011.147.2594.429.001 Allo + PAγ02.000082.00014.599.559 (Allo + PA) x Dxγ03-.000756.000210−3.594.003***Late Extinction*** Interceptγ00-.148.168-.882.392 Dx (0,1)γ011.135.3423.318.005 Allo + PAγ02.000199.0001801.103.289 (Allo + PA) x Dxγ03-.000866.000278−3.114.008[^2]Table 2bExtinction retention deficits as predicted by diagnostic group, (Allo + PA)/5α-DHP, and the interaction between diagnostic group and (Allo + PA)/5α-DHP.Table 2bFixed EffectCoefficientSET-ratioUnadjusted p-valueeFP*Early Extinction*Interceptγ00.038.234.164.872Dx (0,1)γ01.034.272.124.903Ratioγ02.290.354.820.426Ratio x Dxγ03-.293.416-.705.493***Late Extinction***Interceptγ00-.049.272-.182.858Dx (0,1)γ01.161.316.510.618Ratioγ02.344.412.835.418Ratio x DxΓ03-.443.483-.918.374**mLP*Early Extinction***Interceptγ00.020.115.175.863Dx (0,1)γ01.403.1622.495.026Ratioγ02-.006.059-.100.921Ratio x Dxγ03-.165.084−1.954.071***Late Extinction***Interceptγ00-.001.141-.007.994Dx (0,1)γ01.348.1981.758.101Ratioγ02.011.073.149.884Ratio x Dxγ03-.193.103−1.869.083[^3]Table 2cExtinction retention deficits as predicted by diagnostic group, (Allo + PA)/DHEA, and the interaction between diagnostic group and (Allo + PA)/DHEA.Table 2cFixed EffectCoefficientSET-ratioUnadjusted p-valueeFP*Early Extinction*Interceptγ00.184.214.862.403Dx (0,1)γ01-.120.270-.443.664Ratioγ02.015.110.133.896Ratio x Dxγ03-.011.127-.090.929***Late Extinction***Interceptγ00.109.245.443.664Dx (0,1)γ01.065.309.209.837Ratioγ02.026.127.207.839Ratio x Dxγ03-.078.146-.539.598**mLP*Early Extinction***Interceptγ00-.028.147-.191.852Dx (0,1)γ01.171.241.711.489Ratioγ02.007.020.334.743Ratio x Dxγ03-.004.024-.174.865***Late Extinction***Interceptγ00-.096.166-.577.573Dx (0,1)γ01.036.271.134.895Ratioγ02.019.022.842.414Ratio x Dxγ03-.007.027-.277.786[^4]Table 3Spearman correlations between the GABAergic neurosteroid indices of interest and indices of extinction retention.Table 3Spearman Correlation Coefficient (rho)P-value**PTSDeFP*Early Extinction*** Allo + PA.167 (−.559, .748).668 Allo + PA to 5α-DHP Ratio.233 (−.510, .777).546 Allo + PA to DHEA Ratio-.117 (−.725, .593).765***Late Extinction*** Allo + PA-.433 (−.852, .324).244 Allo + PA to 5α-DHP Ratio-.400 (−.841, .360).286 Allo + PA to DHEA Ratio-.650 (−.918, .025).058**mLP*Early Extinction*** Allo + PA-.867 (−.972, −.477).003 Allo + PA to 5α-DHP Ratio-.571 (−.910, .223).139 Allo + PA to DHEA Ratio.083 (−.615, .708).831***Late Extinction*** Allo + PA-.533 (−.884, .203).139 Allo + PA to 5α-DHP Ratio-.382 (−.856, .443).352 Allo + PA to DHEA Ratio.217 (−.523, .770).576  **Trauma ControleFP*Early Extinction*** Allo + PA-.200 (−.763, .536).606 Allo + PA to 5α-DHP Ratio.150 (−.571, .740).700 Allo + PA to DHEA Ratio-.167 (−.748, .559).668***Late Extinction*** Allo + PA-.433 (−.852, .324).244 Allo + PA to 5α-DHP Ratio-.017 (−.673, .655).966 Allo + PA to DHEA Ratio-.317 (−.810, .440).406**mLP*Early Extinction*** Allo + PA.250 (−.497, .784).517 Allo + PA to 5α-DHP Ratio-.381 (−.856, .443).352 Allo + PA to DHEA Ratio.233 (−.510, .777).546***Late Extinction*** Allo + PA.333 (−.425, .817).381 Allo + PA to 5α-DHP Ratio.190 (−.594, .789).651 Allo + PA to DHEA Ratio.233 (−.510, .777).546[^5]Fig. 1The associations between Allo + PA and extinction retention, adjusting for (a) early extinction or (b) late extinction for individuals with and without PTSD \[Note that higher values on the y-axis (i.e., indicating differences between differential SC during extinction retention and early extinction) indicate poorer extinction retention.\].Fig. 1

As predicted, the plasma resting (Allo + PA)/5α-DHP ratio performed like Allo + PA during the mLP in predicting extinction retention ([Table 2](#tbl2b){ref-type="table"}b), although the effects of this ratio appeared to be somewhat weaker (diagnosis main effect controlling for early extinction: β = .403, *p* = .026; diagnosis main effect controlling for late extinction: β = .348, *p* = .101). There was a trend for an interaction between diagnosis and the (Allo + PA)/5α-DHP ratio with extinction retention (calculated in comparison to early extinction) (β = −.165, *p* = .071), such that a higher ratio was associated with better extinction retention in the PTSD, but not TC, group. Parallel results were found for extinction retention based on late extinction (diagnosis main effect: β = .348, *p* = .101; diagnosis X Allo + PA interaction: β = -.193, *p* = .083). [Table 3](#tbl3){ref-type="table"} depicts correlations between the mLP (Allo + PA)/5α-DHP ratio and indices of extinction retention.

In contrast to the above findings for the mLP, the eFP models yielded no significant main effects of diagnostic status, Allo + PA levels, or their interaction for indices of extinction retention ([Table 2](#tbl2a){ref-type="table"}a). Nor were there significant main effects of diagnostic status, the (Allo + PA)/5α-DHP ratio, or their interaction on extinction retention ([Table 2](#tbl2b){ref-type="table"}b). Also, as noted in [Table 2](#tbl2c){ref-type="table"}c, there were no significant main effects of diagnostic status, the plasma resting (Allo + PA)/DHEA ratio, or their interaction on extinction retention. Nevertheless, exploratory correlation analyses for the PTSD group during the eFP revealed a trend for a correlation between resting plasma (Allo + PA)/DHEA ratio and extinction retention (*r* = −.65, *p* = .058) based on late but not early extinction ([Table 3](#tbl3){ref-type="table"}). As can be seen in [Fig. 2](#fig2){ref-type="fig"}a, the difference between the average differential SCRs for extinction retention testing vs. *early* extinction was similar across individuals with PTSD regardless of their (Allo + PA)/DHEA ratio. In contrast ([Fig. 2](#fig2){ref-type="fig"}b), the difference between the average differential SCRs for extinction retention testing vs. *late* extinction decreased for individuals with higher (Allo + PA)/DHEA ratios to levels consistent with achievement of good extinction retention, but increased for individuals with lower ratios.Fig. 2Correlations between the (Allo + PA)/DHEA ratio and extinction retention controlling for (a) early extinction or (b) late extinction \[Note that higher values on the y-axis (i.e., indicating differences between differential SC during extinction retention and early extinction)indicate poorer extinction retention. Participant numbers are provided to allow comparisons between their extinction retention performance compared to late vs. early extinction.\].Fig. 2

4. Discussion {#sec4}
=============

The current study suggests that low resting plasma Allo + PA levels in women with PTSD, apparently related to deficient 3α-HSD activity, are associated with extinction retention deficits during the mLP of the menstrual cycle when 17β-estradiol and progesterone levels are both high and stable ([@bib29]). Studies in rodents ([@bib50]) and in women exposed to extreme stress ([@bib37]) suggest that peripheral deficits in the capacity for Allo and PA synthesis are mirrored in the CNS. A limited capacity for intraneuronal Allo + PA synthesis has been shown to forestall development of long-term depression (LTD) and/or emergence of long-term potentiation (LTP) interference ([@bib15]). LTD and LTP are critical to extinction ([@bib18]). In turn, studies suggest that the emergence of LTP interference across learning (e.g., extinction learning) may protect the recently strengthened or weakened synapses from further modulation (i.e., from being "overwritten") during memory consolidation ([@bib36]; [@bib48]; [@bib7]). Thus, it follows that adequate neuronal synthesis of the GABAergic neurosteroids, Allo and PA, may support both extinction learning and the retention of extinction learning, as suggested by this study.

In contrast, during the eFP, when progesterone and estradiol levels are low, Allo + PA levels alone were not a significant predictor of extinction retention. However, the ratio of Allo + PA to DHEA was positively associated with extinction retention based on late but not early extinction. As levels of Allo + PA (which facilitate GABA~A~ receptor function and antagonize NMDA receptor function) and DHEA (which antagonizes GABA~A~ receptor function and facilitates NMDA receptor function) are comparable during the eFP ([Table 1](#tbl1){ref-type="table"}), it is possible that their effects compete. Thus, a low ratio of inhibitory vs. excitatory neurosteroids may impact net neuronal excitability with effects on a) neuronal LTD or LTP interference, as well as b) frontal lobe and hippocampal circuits that inhibit amygdala reactivity during extinction learning or extinction recall. Consistent with our hypothesis regarding potential menstrual phase-specific effects of DHEA, we saw a trend for a relationship between the (Allo + PA)/DHEA ratio and extinction retention during the eFP when Allo + PA and DHEA levels are comparable. We did not see a relationship between the (Allo + PA)/DHEA ratio and extinction retention during the mLP when plasma Allo + PA levels are an order of magnitude higher than plasma DHEA levels.

Our previously published work based on a larger subsample (n = 32) of the parent study ([@bib29]) examined only the effects of diagnostic status and menstrual phase on extinction retention. Consistent with earlier work by other investigators ([@bib22]), that study showed healthy trauma-exposed women to have better extinction retention during the mLP when both estradiol and progesterone levels are high, compared to the eFP when levels of both are at their lowest. In contrast, women with PTSD performed worse during the mLP than the eFP (when their performance was comparable to that of healthy women). 17β-estradiol has been shown to upregulate 3α-HSD expression in the brain of female rodents ([@bib23]). It is possible that effects of 17β-estradiol on 3α-HSD expression are compromised during the mLP in a subpopulation of women with PTSD. A variety of factors may be responsible ([@bib51]). For example, possession of a loss-of function polymorphism in the estrogen sensitive pituitary adenylate cyclase-activating polypeptide (PACAP) receptor (PAC1) has been associated with increased risk for PTSD in women, as well as with poor safety signal learning during fear acquisition ([@bib40]). As previously discussed ([@bib36]), this polymorphism would be expected to reduce on-demand neurosteroidogenesis. Reduced glucocorticoid receptor signaling due to deficits in cortisol synthesis, as seen in individuals with various forms of congenital adrenal hyperplasia (CAH) or genetically impaired glucocorticoid receptor function, also may reduce 3α-HSD expression and Allo + PA synthesis under stress ([@bib14]). For example, common variants of the *FKBP5* gene are associated with higher *FKBP5* protein expression, which results in impaired glucocorticoid receptor function. These variants also have been associated with increased risk for PTSD, both directly and interactively with early life stress ([@bib3]; [@bib11]; [@bib49]). In addition, deficits in the reduced form of nicotinamide adenine dinucleotide phosphate (i.e., NADPH), a necessary cofactor for the reductive function of 3α-HSD, or possession of a loss-of-function polymorphism in the 3α-HSD gene itself, including in the steroid response element that binds estradiol, might contribute to Allo + PA deficits or a reduced ratio of Allo + PA to DHEA ([@bib27]). Finally, well described but relatively rare, deficiencies in 3β-HSD function that result in elevated DHEA synthesis ([@bib1]) would be expected to limit synthesis of Allo and PA and, thereby, may contribute to increased PTSD risk, severity or chronicity. Indeed, homozygosity for 3β-HSD deficiency has been associated with increased rates of depression, alcohol misuse and suicidality ([@bib1]), which are common comorbidities of PTSD. Thus, heterozygosity for 3β-HSD deficiency, which may present with hyperandrogenism, also should be investigated for its possible relationship to PTSD ([@bib1]; [@bib25]).

Examination of the impact of neurosteroids on extinction retention is a relatively new area of research in humans. As discussed above, the current study has a small sample size due to the number of SC non-responders and individuals for whom we were unable to obtain blood samples. Given this limited sample size, the present findings must be viewed with caution and in need of replication. However, the findings agree with previous preclinical work in male rodents demonstrating an association between experimentally induced reductions in brain Allo levels and impaired extinction retention in similarly sized cohorts ([@bib32]; [@bib28]; [@bib43]; [@bib24]). As noted in the introduction, these preclinical studies also suggest that it might be possible to improve extinction retention in women with deficient synthesis of Allo and PA through interventions aimed at increasing levels of these GABAergic neurosteroids. However, the timing and dose of such GABAergic neurosteroid based treatments may be critical and bear close investigation in humans for their impact on PTSD symptom severity, as well as learning and memory processes inherent to PTSD recovery.

There is a long tradition of using laboratory extinction models to inform mechanisms underlying exposure therapy efficacy in humans ([@bib13]). Although exposure therapies are first line treatments for PTSD and often produce significant symptom reductions ([@bib34]), they have a high dropout rate ([@bib12]) and most clients are not asymptomatic at the end of treatment ([@bib2]; [@bib42]). Consequently, research is increasingly being targeted toward development of adjunctive pharmacological interventions that might enhance exposure therapy outcomes. Several clinical trials have tested D-cycloserine (i.e., a partial NMDA agonist) and have shown variable results ([@bib19]; [@bib47]). Another recent study showed promising effects for propranolol (a noradrenergic beta-receptor blocker) in enhancing the efficacy of written exposure treatment for PTSD ([@bib6]). Findings from the current study provide preliminary support for Allo as another promising pharmacological adjunctive treatment to enhance exposure therapy outcomes for PTSD. Allo + PA levels also have been shown to increase in response to non-pharmacological interventions such as brief, intense exercise ([@bib44]), which was recently shown in a pilot study to improve outcomes in women with PTSD treated with Prolonged Exposure therapy ([@bib35]). Pharmacological Allo-related therapies are also currently being used or investigated for treatment of disorders other than PTSD, such as major depression, postpartum depression, and premenstrual dysphoric disorder ([@bib9]). These disorders have been associated with decreases in CSF or plasma Allo levels in some studies, and all have substantially increased co-prevalence with PTSD among women. These observations as well as the results of the current study point to the potential importance of developing clinically feasible tests for deficient GABAergic steroid synthesis that may be useful in the development and prescription of transdiagnostic Allo-based treatments.

5. Conclusion {#sec5}
=============

The findings of this study suggest that reduced Allo + PA levels may contribute to extinction retention deficits observed during the mLP in women with PTSD. During the eFP, it appears that a low resting plasma (Allo + PA)/DHEA ratio might contribute to extinction retention deficits in women with PTSD. Together with repeatedly observed associations between GABAergic neurosteroid synthesis deficits and PTSD severity in men and women, our findings suggest a mechanism that may link early post-trauma PTSD severity with risk for chronic PTSD ([@bib46]). The present work also supports the importance of investigating interventions that may increase Allo + PA levels in order to reduce PTSD risk and enhance PTSD recovery.
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[^1]: *Note.* Allo: allopregnanolone; PA: pregnanolone; 5α-DHP: 5α-dihydroprogesterone; DHEA: dehydroepiandrosterone. Two participants were missing the mid-luteal phase 5α-DHP measurement (1 missing in the PTSD group; 1 missing in the trauma control group). P values were determined using the Wilcoxon signed rank test.

[^2]: *Note.* The dependent variable is the skin conductance value for extinction retention (see Methods). Diagnostic group (Dx) is coded 0 for trauma control (TC: n = 9) and 1 for posttraumatic stress disorder (PTSD: n = 9). eFP: early follicular phase; mLP: mid-luteal phase; Allo: allopregnanolone; PA: pregnanolone.

[^3]: *Note.* The dependent variable is the skin conductance value for extinction retention (see Methods). Diagnostic group (Dx) is coded 0 for trauma control (TC: n = 9) and 1 for traumatic stress disorder (PTSD: n = 9). eFP: early follicular phase; mLP: mid-luteal phase; Allo: allopregnanolone; PA: pregnanolone; 5α-DHP: 5α-dihydroprogesterone.

[^4]: *Note.* The dependent variable is the skin conductance value for extinction retention (see Methods). Diagnostic group (Dx) is coded 0 for trauma control (TC: n = 9) and 1 for traumatic stress disorder (PTSD: n = 9). eFP: early follicular phase; mLP: mid-luteal phase; Allo: allopregnanolone; PA: pregnanolone; DHEA: dehydroepiandrosterone.

[^5]: *Note.* CI = confidence interval; eFP: early follicular phase; mLP: mid-luteal phase; Allo: allopregnanolone; PA: pregnanolone; 5α-DHP: 5α-dihydroprogesterone; DHEA: dehydroepiandrosterone.
